Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTSCAP: Piperacillin/Tazobactam Monotherapy vs Combination in sCAP
NCT06977347Not yet recruiting
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Randomised trial of piperacillin + tazobactam in Community-acquired pneumonia (CAP) (2 arms). Primary endpoint: All-cause 28-day mortality. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
piperacillin + tazobactam
03
Conditions
Community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT06977347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06977347.